{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:19:37Z","timestamp":1784344777484,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40268-020-00307-2","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T16:36:45Z","timestamp":1588005405000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers"],"prefix":"10.1007","volume":"20","author":[{"given":"Jacinthe","family":"Leclerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Rochette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Gu\u00e9nette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Beaudoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"307_CR1","unstructured":"Gouvernement du Qu\u00e9bec. Mesure d\u2019\u00e9conomie concernant les m\u00e9dicaments - Nouvelles r\u00e8gles concernant le recours \u00e0 la mention ne pas substituer.\u00a02015.\u00a0https:\/\/www.ramq.gouv.qc.ca\/SiteCollectionDocuments\/professionnels\/infolettres\/2015\/info265-4.pdf.\u00a0Accessed 20 Apr 2020."},{"key":"307_CR2","unstructured":"Apotex inc. Monographie de produit APO-LOSARTAN. 2013.\u00a0https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/base-donnees-produits-pharmaceutiques.html. Accessed 18 Nov 2015."},{"key":"307_CR3","unstructured":"Mylan Pharmaceuticals ULC. Monographie de produit Mylan-valsartan. 2015. https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/base-donnees-produits-pharmaceutiques.html. Accessed 18\u00a0Nov 2015."},{"key":"307_CR4","unstructured":"Sandoz Canada Inc. Monographie de produit Sandoz Cand\u00e9sartan (cand\u00e9sartan). 2016.\u00a0https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/base-donnees-produits-pharmaceutiques.html. Accessed 30 Sept 2017."},{"issue":"8","key":"307_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40266-019-00679-4","volume":"36","author":"J Leclerc","year":"2019","unstructured":"Leclerc J, Blais C, Rochette L, Hamel D, Guenette L, Poirier P. Did generic clopidogrel commercialization affect trends of er consultations and hospitalizations in the population treated with clopidogrel? Drugs Aging. 2019;36(8):759\u201368.","journal-title":"Drugs Aging"},{"key":"307_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCOUTCOMES.117.003891","volume":"10","author":"J Leclerc","year":"2017","unstructured":"Leclerc J, Blais C, Rochette L, Hamel D, Gu\u00e9nette L, Poirier P. Impact of the commercialization of three generic angiotensin II receptor blockers on adverse events in Quebec, Canada: a population-based time series analysis. Circ Cardiovasc Qual Outcomes. 2017;10:1\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"307_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1345\/aph.1P593","volume":"45","author":"SR Ghate","year":"2011","unstructured":"Ghate SR, Biskupiak JE, Ye X, Hagan M, Kwong WJ, Fox ES, Brixner DI. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. Ann Pharmacother. 2011;45:701\u201312.","journal-title":"Ann Pharmacother"},{"key":"307_CR8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1345\/aph.1Q472","volume":"46","author":"WJ Kwong","year":"2012","unstructured":"Kwong WJ, Kamat S, Fang C. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients. Ann Pharmacother. 2012;46:1609\u201316.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"307_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40256-018-0309-9","volume":"19","author":"J Leclerc","year":"2018","unstructured":"Leclerc J, Blais C, Rochette L, Hamel D, Gu\u00e9nette L, Poirier P. Trends in hospital visits for generic and brand-name warfarin users in Quebec, Canada; a population-based time series analysis. Am J Cardiovasc Drugs. 2018;19(3):287\u201397.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"1370","key":"307_CR10","first-page":"e13","volume":"34","author":"J Leclerc","year":"2018","unstructured":"Leclerc J. Recall of NDMA-contaminated pseudogeneric valsartan; best generics finally no better than others? Can J Cardiol. 2018;34(1370):e13.","journal-title":"Can J Cardiol"},{"key":"307_CR11","unstructured":"Extance A. Sartan drug contamination brings cancer uncertainty. 2018.\u00a0https:\/\/www.chemistryworld.com\/news\/sartan-drug-contamination-brings-cancer-uncertainty\/3009849.article. Accessed 3 Apr 2019."},{"key":"307_CR12","unstructured":"European Medicine Agency. Update on review of recalled valsartan medicines. 2018.\u00a0http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2018\/08\/news_detail_003000.jsp&mid=WC0b01ac058004d5c1. Accessed 6 Aug 2018."},{"key":"307_CR13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.24095\/hpcdp.34.4.06","volume":"34","author":"C Blais","year":"2014","unstructured":"Blais C, Jean S, Sirois C, Rochette L, Plante C, Larocque I, et al. Quebec Integrated Chronic Disease Surveillance System (QICDSS), an innovative approach. Chronic diseases and injuries in Canada. 2014;34:226\u201335.","journal-title":"Chronic diseases and injuries in Canada."},{"key":"307_CR14","unstructured":"Saint-Laurent D, Blais C, Jean S, Sirois C, Rochette L and \u00c9mond V. Le mod\u00e8le qu\u00e9b\u00e9cois de surveillance des maladies chroniques bas\u00e9 sur l\u2019utilisation des donn\u00e9es m\u00e9dico-administratives jumel\u00e9es. Bulletin \u00e9pid\u00e9miologique hebdomadaire. 2013;Hors-s\u00e9rie:4-8."},{"key":"307_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/9781118344828","volume-title":"Textbook of pharmacoepidemiology","author":"BL Strom","year":"2013","unstructured":"Strom BL. Chapter 2. Study designs available for pharmacoepidemiologic studies. In: Strom BL, Kimmel SE, Hennessy S, editors. Textbook of pharmacoepidemiology. 2nd ed. Chichester: Wiley Blackwell; 2013. p. 456.","edition":"2"},{"key":"307_CR16","unstructured":"Programme d\u2019\u00e9ducation canadien sur l\u2019hypertension. Guide de pratique clinique d\u2019Hypertension Canada sur la prise en charge de l\u2019hypertension. 2017.\u00a0http:\/\/guidelines.hypertension.ca\/ressources-francaises\/. Accessed 11 Sept 2017."},{"issue":"11","key":"307_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cjca.2017.08.022","volume":"33","author":"JA Ezekowitz","year":"2017","unstructured":"Ezekowitz JA, O\u2019Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33(11):1342\u2013433.","journal-title":"Can J Cardiol"},{"key":"307_CR18","unstructured":"Sant\u00e9 Canada. Ligne directrice - Normes en mati\u00e8re d\u2019\u00e9tudes de biodisponibilit\u00e9s comparatives: Formes pharmaceutiques de m\u00e9dicaments \u00e0 effets syst\u00e9miques. M\u00e9dicaments et produits de sant\u00e9. 2018.\u00a0https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/demandes-presentations\/lignes-directrices\/biodisponibilite-bioequivalence\/normes-matiere-etudes-biodisponibilite-comparatives-formes-pharmaceutiques-medicaments-effets-systemiques.html. Accessed 29 Oct 2018."},{"key":"307_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1046\/j.1365-2710.2002.00411.x","volume":"27","author":"BA Morningstar","year":"2002","unstructured":"Morningstar BA, Sketris IS, Kephart G, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther. 2002;27:213\u201320.","journal-title":"J Clin Pharm Ther."},{"key":"307_CR20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/aje\/kwi307","volume":"162","author":"Z Zhou","year":"2005","unstructured":"Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005;162:1016\u201323.","journal-title":"Am J Epidemiol"},{"key":"307_CR21","first-page":"85","volume":"20","author":"R Pampalon","year":"2009","unstructured":"Pampalon R, Hamel D, Gamache P. A comparison of individual and area-based socio-economic data for monitoring social inequalities in health. Health Rep. 2009;20:85\u201394.","journal-title":"Health Rep"},{"key":"307_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-1353-0","volume-title":"Regression methods in biostatistics: linear, logistic, survival, and repeated measures models","author":"E Vittinghoff","year":"2012","unstructured":"Vittinghoff E. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. New York: Springer; 2012."},{"key":"307_CR23","unstructured":"Novartis Pharmaceuticals Canada Inc. Monographie de produit DIOVAN (valsartan). 2015.\u00a0https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/base-donnees-produits-pharmaceutiques.html. Accessed 18 Nov 2015."},{"key":"307_CR24","unstructured":"AstraZeneca Inc. Monographie ATACAND (cand\u00e9sartan cilex\u00e9til). 2016.\u00a0https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/base-donnees-produits-pharmaceutiques.html.\u00a0Accessed 30 Sept 2017."},{"key":"307_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/aje\/kwv445","volume":"184","author":"ME Karim","year":"2016","unstructured":"Karim ME, Gustafson P, Petkau J, Tremlett H. Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. Am J Epidemiol. 2016;184:325\u201335.","journal-title":"Am J Epidemiol"},{"key":"307_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.addr.2003.10.008","volume":"56","author":"D Singhal","year":"2004","unstructured":"Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev. 2004;56:335\u201347.","journal-title":"Adv Drug Deliv Rev"},{"key":"307_CR27","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1185\/03007990903116867","volume":"25","author":"PA Meredith","year":"2009","unstructured":"Meredith PA. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin. 2009;25:2179\u201389.","journal-title":"Curr Med Res Opin"},{"key":"307_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","volume":"31","author":"L Manzoli","year":"2016","unstructured":"Manzoli L, Flacco ME, Boccia S, D\u2019Andrea E, Panic N, Marzuillo C, et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31:351\u201368.","journal-title":"Eur J Epidemiol"},{"key":"307_CR29","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1001\/jama.2008.758","volume":"300","author":"A Kesselheim","year":"2008","unstructured":"Kesselheim A, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514\u201326.","journal-title":"JAMA"},{"issue":"4","key":"307_CR30","doi-asserted-by":"publisher","first-page":"e003350","DOI":"10.1161\/JAHA.116.003350","volume":"5","author":"C Jackevicius","year":"2016","unstructured":"Jackevicius C, Tu JV, Krumholz HM, Austin PC, Ross JS, Stukel TA, et al. Comparative effectiveness of generic atorvastatin and lipitor(r) in patients hospitalized with an acute coronary syndrome. J Am Heart Assoc. 2016;5(4):e003350.","journal-title":"J Am Heart Assoc"},{"key":"307_CR31","doi-asserted-by":"crossref","first-page":"e004194","DOI":"10.1161\/CIRCOUTCOMES.117.004194","volume":"11","author":"DT Ko","year":"2018","unstructured":"Ko DT, Krumholz HM, Tu JV, Austin PC, Stukel TA, Koh M, et al. Clinical outcomes of plavix and generic clopidogrel for patients hospitalized with an acute coronary syndrome. Circ Cardiovasc Qual Outcomes. 2018;11:e004194.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"307_CR32","unstructured":"Gouvernement du Canada. Adverse reaction and medical device problem reporting. 2017.\u00a0https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/adverse-reaction-reporting.html. Accessed 26 Sept 2017."},{"key":"307_CR33","doi-asserted-by":"crossref","unstructured":"Alatawi Y, Rahman M, Cheng N, Qian J, Hansen R, Seoane-Vazquez E, et al. Brand vs. generic adverse event reporting patterns: an authorized generic-controlled evaluation of cardiovascular medications. J Am Pharm Assoc. 2017;57.","DOI":"10.1111\/jcpt.12646"},{"key":"307_CR34","first-page":"456","volume-title":"Textbook of pharmacoepidemiology","author":"GJD Pan","year":"2013","unstructured":"Pan GJD, Lindquist M, Gelperin K. Chapter 7. Postmarketing spontaneous pharmacovigilance reporting systems. In: Strom BL, Kimmel SE, Hennessy S, editors. Textbook of pharmacoepidemiology. 2nd ed. Chichester: Wiley; 2013. p. 456.","edition":"2"},{"key":"307_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/9781118344828","volume-title":"Textbook of pharmacoepidemiology","author":"BL Strom","year":"2013","unstructured":"Strom BL, Kimmel SE, Hennessy S. Textbook of pharmacoepidemiology. Chichester: Wiley Blackwell; 2013."},{"key":"307_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0895-4356(94)00234-H","volume":"48","author":"R Tamblyn","year":"1995","unstructured":"Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:999\u20131009.","journal-title":"J Clin Epidemiol"},{"key":"307_CR37","doi-asserted-by":"publisher","first-page":"E276","DOI":"10.1503\/cmaj.170385","volume":"190","author":"FA McAlister","year":"2018","unstructured":"McAlister FA, Bakal JA, Green L, Bahler B, Lewanczuk R. The effect of provider affiliation with a primary care network on emergency department visits and hospital admissions. Can Med Assoc J. 2018;190:E276\u201384.","journal-title":"Can Med Assoc J"},{"key":"307_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cjca.2011.10.005","volume":"28","author":"L Lambert","year":"2012","unstructured":"Lambert L, Blais C, Hamel D, Brown K, Rinfret S, Cartier R, et al. Evaluation of care and surveillance of cardiovascular disease: can we trust medico-administrative hospital data? Can J Cardiol. 2012;28:162\u20138.","journal-title":"Can J Cardiol"},{"key":"307_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0895-4356(03)00246-4","volume":"57","author":"M Wilchesky","year":"2004","unstructured":"Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004;57:131\u201341.","journal-title":"J Clin Epidemiol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00307-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00307-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00307-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T10:36:41Z","timestamp":1666435001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00307-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00307-2","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"27 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr Poirier has received honorarium for continuing medical education\/consulting\/expert events from Abbott Vascular, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, NovoNordisk, Pfizer, Roche, Sanofi-Aventis, Servier, and Valeant. The industry has no regard\/power in the decisions made through this project. Dr Leclerc is a Professor of Nursing at Universit\u00e9 du Qu\u00e9bec \u00e0 Trois-Rivi\u00e8res. Within her role of Professor, she provides continuous medical education sessions for health care professionals, accredited by the F\u00e9d\u00e9ration des m\u00e9decins omnipraticiens du Qu\u00e9bec and its local affiliates, and statistical expertise on Data Safety Monitoring Board Committees managed by JSS Medical Research, a contract research organization that executes clinical trials\/studies for pharmaceutical and biotechnology companies, as well as universities and hospitals. Claudia Blais, Louis Rochette, Denis Hamel, Line Gu\u00e9nette, and Claudia Beaudoin have no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received for this study as the project is part of the continuous chronic disease surveillance mandate in Quebec, Canada. All surveillance activities of this mandate are approved by the provincial Ethic Committee of Public Health. No informed consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and Funding"}}]}}